308M-1
Oct-2 (MRQ-2) Mouse Monoclonal Antibody
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
MRQ-2, monoclonal
Application:
IHC (p)
Citations:
4
biological source
mouse
conjugate
unconjugated
antibody form
diluted ascites fluid
antibody product type
primary antibodies
clone
MRQ-2, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (308M-14), vial of 0.5 mL concentrate (308M-15), bottle of 1.0 mL predilute (308M-17), vial of 1.0 mL concentrate (308M-16), bottle of 7.0 mL predilute (308M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgG1κ
control
tonsil
shipped in
wet ice
storage temp.
2-8°C
visualization
nuclear
Gene Information
human ... POU2F2(5452)
Related Categories
General description
Octamer-binding transcription factor-2 (Oct-2) is a transcription factor of the POU homeo-domain family. It binds to Ig gene octamer sites and plays a crucial role in B-cell development and differentiation, as well as in B-cell identity. Oct-2 is expressed in a subset of normal B-lymphocytes and is expressed in various B-cell lymphomas as well as nodular lymphocyte predominant Hodgkin lymphoma, while it is typically not expressed in the Reed–Sternberg and Hodgkin (RS/H) cells of classical Hodgkin lymphoma.
Oct-2 is a transcription factor of the POU homeo-domain family that binds to the Ig gene octamer sites, regulating B-cell-specific genes. These are involved in proliferation and differentiation and despite the scarce evidence for Oct-2 expression in T cells, it has been shown that this factor participates in transcriptional regulation during T-cell activation. Oct-2 activity is dependent on phosphorylation and alternatitive splicing, although it seems that the level of its expression can be used as a marker of B-cell lineage and differentiation. The following show high levels of Oct-2 expression: germinal center B-cells, mantle B-cells, monocytoid B-cells, and plasma cells. Various lymphomas are also positive for this marker including the following: B-chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, plasmacytoma, Burkitt lymphoma, diffuse large cell lymphoma, diffuse large B-cell lymphoma, T-cell rich B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, classic Hodgkin lymphoma.
Several studies of Oct-2 expression have shown a low level expression in pre-B, T-cell, myelomonocytic, and epithelial cell lines, whereas all mature B-cell lines display high levels of expression. Analysis of Oct-2 expression in primary Hodgkin’s lymphoma (HLs) and cell lines derived from it showed that the tumor cells analyzed had high levels of expression and activity, suggesting a common B-cell origin for all types of HLs.
Associated products: bcl-6, CD20, CD79a, PAX-5, BOB.1
Oct-2 is a transcription factor of the POU homeo-domain family that binds to the Ig gene octamer sites, regulating B-cell-specific genes. These are involved in proliferation and differentiation and despite the scarce evidence for Oct-2 expression in T cells, it has been shown that this factor participates in transcriptional regulation during T-cell activation. Oct-2 activity is dependent on phosphorylation and alternatitive splicing, although it seems that the level of its expression can be used as a marker of B-cell lineage and differentiation. The following show high levels of Oct-2 expression: germinal center B-cells, mantle B-cells, monocytoid B-cells, and plasma cells. Various lymphomas are also positive for this marker including the following: B-chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, plasmacytoma, Burkitt lymphoma, diffuse large cell lymphoma, diffuse large B-cell lymphoma, T-cell rich B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, classic Hodgkin lymphoma.
Several studies of Oct-2 expression have shown a low level expression in pre-B, T-cell, myelomonocytic, and epithelial cell lines, whereas all mature B-cell lines display high levels of expression. Analysis of Oct-2 expression in primary Hodgkin’s lymphoma (HLs) and cell lines derived from it showed that the tumor cells analyzed had high levels of expression and activity, suggesting a common B-cell origin for all types of HLs.
Associated products: bcl-6, CD20, CD79a, PAX-5, BOB.1
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Oct-2 Positive Control Slides, Product No. 308S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk
WGK 2
Regulatory Information
监管及禁止进口产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mónica García-Cosío et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 17(12), 1531-1538 (2004-07-17)
Hodgkin's lymphoma can be considered in most cases a B-cell lymphoma due to the presence of potentially functional immunoglobulin (Ig) gene rearrangements in the neoplastic cells. In contrast to lymphocyte-predominant Hodgkin's lymphoma, Hodgkin/Reed-Sternberg (HRS) cells from classical Hodgkin's lymphoma have
Sarah E Gibson et al.
American journal of clinical pathology, 126(6), 916-924 (2006-11-01)
The aberrant expression of the B-cell transcription factor PAX5 has been described in a subset of acute myeloid leukemia (AML) with t(8;21)(q22;q22) in association with B-cell antigen expression. However, the expression of other B cell-associated transcription factors, particularly OCT-2 and
Christian Hallermann et al.
Journal of the American Academy of Dermatology, 56(4), 588-597 (2007-02-10)
There is a growing body of literature that has enhanced our understanding of the biology of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) including in the context of gene profiling studies. Recent studies have demonstrated an activated proliferation profile associated
Patrick Browne et al.
American journal of clinical pathology, 120(5), 767-777 (2003-11-12)
Even with routine immunohistochemical evaluation, distinguishing classic Hodgkin lymphoma (CHL) from diffuse large B-cell lymphoma (DLBCL) or anaplastic large cell lymphoma (ALCL) can be difficult. In these cases, the transcription factors (B cell-specific activator protein [BSAP], octamer-binding transcription factor 2
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 308M-17 | 0841683134756 |
| 308M-14 | 0841683134725 |
| 308M-16 | 0841683134749 |
| 308M-15 | 0841683134732 |
| 308M-16-RUO | 04061836531409 |
| 308M-18 | 0841683134763 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service